Relypsa is a clinical-stage biopharmaceutical company leading the discovery and development of novel non-absorbed polymeric drugs for important applications in cardiovascular and renal diseases. Relypsa's lead product candidate is RLY5016, a non- absorbed potassium binder for the treatment of hyperkalemia. Relypsa is pursuing the discovery of additional product candidates through use of its proprietary polymer platform. Privately-held, Relypsa’s investors include: OrbiMed, 5AM Ventures, Delphi Ventures, Mediphase Venture Partners, New Leaf Venture Partners, Sprout Group and Amgen.

October 25, 2011 ^NEW
Wilhelm Stahl, Ph.D. Joins Relypsa as Senior Vice President, Pharmaceutical Operation

June 28 , 2011
Relypsa Begins Treatment in AMETHYST-DN Trial of RLY5016 for Hyperkalemia in Diabetic Nephropathy Patients with Chronic Kidney Disease

May 23, 2011
Relypsa Announces Presentation of Positive Phase 2 Results for RLY5016 at American Society of Hypertension Meeting

May 19, 2011
Relypsa Adds Key Leadership Positions to Support Late-Stage Development and Pre-Launch Commercial Activities